Abstract

Subunit vaccines have been investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but have rarely been clinically translated. By conjugating molecular vaccines with Evans blue (EB) into albumin-binding vaccines (AlbiVax), here we develop clinically promising albumin/AlbiVax nanocomplexes that self-assemble in vivo from AlbiVax and endogenous albumin for efficient vaccine delivery and potent cancer immunotherapy. PET pharmacoimaging, super-resolution microscopies, and flow cytometry reveal almost 100-fold more efficient co-delivery of CpG and antigens (Ags) to lymph nodes (LNs) by albumin/AlbiVax than benchmark incomplete Freund’s adjuvant (IFA). Albumin/AlbiVax elicits ~10 times more frequent peripheral antigen-specific CD8+ cytotoxic T lymphocytes with immune memory than IFA-emulsifying vaccines. Albumin/AlbiVax specifically inhibits progression of established primary or metastatic EG7.OVA, B16F10, and MC38 tumors; combination with anti-PD-1 and/or Abraxane further potentiates immunotherapy and eradicates most MC38 tumors. Albumin/AlbiVax nanocomplexes are thus a robust platform for combination cancer immunotherapy.

Details

Title
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Author
Zhu, Guizhi 1   VIAFID ORCID Logo  ; Lynn, Geoffrey M 2 ; Jacobson, Orit 1 ; Chen, Kai 3   VIAFID ORCID Logo  ; Liu, Yi 4 ; Zhang, Huimin 1 ; Ma, Ying 1 ; Zhang, Fuwu 1 ; Tian, Rui 1 ; Ni, Qianqian 1 ; Cheng, Siyuan 1 ; Wang, Zhantong 5 ; Lu, Nan 1 ; Yung, Bryant C 1 ; Wang, Zhe 1 ; Lang, Lixin 1 ; Fu, Xiao 6 ; Jin, Albert 6   VIAFID ORCID Logo  ; Weiss, Ido D 7 ; Vishwasrao, Harshad 8 ; Niu, Gang 1 ; Shroff, Hari 9 ; Klinman, Dennis M 10 ; Seder, Robert A 2 ; Chen, Xiaoyuan 1   VIAFID ORCID Logo 

 Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA 
 Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA 
 Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA 
 Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA; School of Engineering, China Pharmaceutical University, Nanjing, China 
 Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China 
 Laboratory of Cellular Imaging and Macromolecular Biophysics, NIBIB, NIH, Bethesda, MD, USA 
 Laboratory of Molecular Immunology, NIAID, NIH, Bethesda, MD, USA 
 Advanced Imaging and Microscopy Resource, National Institutes of Health, Bethesda, MD, USA 
 Advanced Imaging and Microscopy Resource, National Institutes of Health, Bethesda, MD, USA; Section on High Resolution Optical Imaging, NIBIB, NIH, Bethesda, MD, USA 
10  Cancer and Inflammation Program, National Cancer Institute, Frederick, MD, USA 
Pages
1-15
Publication year
2017
Publication date
Dec 2017
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1983416057
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.